Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson demonstrated robust financial performance in its second quarter of 2025, reporting innovative medicine revenues of $15.20 billion, surpassing consensus expectations, which reflects strong operational growth. The company's management has raised its full-year 2025 sales guidance to a range of $93.2 billion to $93.6 billion, attributing approximately $900 million of this increase to operational strength and another $1.1 billion to favorable currency fluctuations. With anticipations of stronger operational sales growth in the second half of 2025 compared to the first half and positive momentum in its MedTech and Vision segments, Johnson & Johnson is poised for continued growth through 2026.

Bears say

Johnson & Johnson's stock outlook is negatively influenced by a projected decline in organic revenue growth, particularly due to lower contributions from its pharmaceutical pipeline and the impact of upcoming patent expirations expected to lead to less than $57 billion in revenue by 2025. The company's MedTech segment is facing headwinds from competitive pressures, which may hinder the uptake of new products, and concerns over M&A integration could disrupt operational efficiency. Additionally, higher litigation and settlement costs, combined with disappointing product launches, create further risks that could adversely affect sales and earnings forecasts.

JNJ has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 15 analysts, JNJ has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.